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Abstract 30 
 31 
L-ficolin is a liver-expressed soluble pattern recognition molecule that contributes to innate 32 
immune defense against microorganisms. It is well described that binding of L-ficolin to 33 
specific pathogen-associated molecular patterns activates the lectin complement pathway 34 
resulting in opsonization and lysis of pathogens. In this study we demonstrated that in 35 
addition to this indirect effect, L-ficolin has a direct neutralizing effect against Hepatitis C 36 
Virus (HCV) entry. Specific, dose-dependent binding of recombinant L-ficolin to HCV 37 
glycoproteins E1 and E2 was observed. This interaction was inhibited by soluble L-ficolin 38 
ligands. Interaction of L-ficolin with E1 and E2 potently inhibited entry of retroviral 39 
pseudoparticles bearing these glycoproteins. L-ficolin also inhibited entry of cell-cultured 40 
HCV in a calcium-dependent manner. Neutralizing concentrations of L-ficolin were found 41 
to be circulating in the serum of HCV-infected individuals.  This is the first description of 42 
direct neutralization of HCV entry by a ficolin and highlights a novel role for L-ficolin as a 43 
virus entry inhibitor. 44 
 45 
  46 
Introduction  47 
Chronic Hepatitis C Virus (HCV) infection affects approximately 130 million people. 48 
Chronic infection is a risk factor for cirrhosis and hepatocellular carcinoma, resulting in the 49 
requirement for liver transplantation [1]. Entry inhibitors are an attractive treatment in the 50 
clinical setting of liver transplantation, where they might prevent infection of transplanted 51 
tissue. Current therapies target the HCV NS3 protease and the NS5B polymerase [2], but 52 
cannot prevent initial infection. 53 
 54 
Binding of HCV envelope glycoproteins E1 and E2 to cellular CD81 and SR-B1 is 55 
essential for HCV entry, and antibodies that inhibit these interactions neutralize entry 56 
(reviewed in [3]). These glycoproteins are targets for therapeutic intervention and host 57 
immunity [4,5]. They possess up to 5 and 11 N-linked glycosylation sites, respectively [6]. 58 
These glycans are structurally heterogeneous [7], and contribute to glycoprotein 59 
biosynthesis, modulation of infectivity and evasion of neutralizing antibodies [8,9]. Many 60 
glycosylation sites are highly conserved across genetically diverse HCV isolates [10]. This 61 
makes them attractive targets for anti-viral drug development. The lectins cyanovirin-N 62 
[11], griffithsin [12] and mannose binding lectin [10] all inhibit entry by binding to these 63 
glycans.  64 
 65 
Ficolins are a family of serum proteins functionally and structurally related to the 66 
collectins, sharing quaternary structure with mannose binding lectin (MBL) and 67 
complement component C1q [13]. They consist of disulfide-linked 35kDa polypeptides 68 
organized into trimers. Oligomers of these three polypeptides form functional dodecamers 69 
[13]. They bind glycan-containing pathogen-associated molecular patterns (PAMPs) and 70 
activate the complement cascade. The carbohydrate-binding activity is attributed to the C-71 
terminal fibrinogen-like binding domain that has general specificity for N-acetyl groups on 72 
the outer walls of microorganisms [14]. In humans, three ficolins have been identified; L-73 
ficolin, M-ficolin, and H-ficolin [15]. H-ficolin and L-ficolin are expressed by hepatocytes. 74 
L-ficolin has a broad binding specificity for targets including galactose, β-glucan, 75 
acetylated compounds, N-acetylglucosamine and N-acetylcysteine. Binding is mediated by 76 
four binding sites in the C-terminal fibrinogen-like binding domain, some of which require 77 
calcium for interaction [16]. L-ficolin associates with MBL-associated serine proteases 78 
(MASPs), resulting in complement activation, phagocytosis and clearance of pathogens 79 
bearing N-acetylated structures such as N-Acetyl glucosamine (GlcNAc) [17,18], a major 80 
component of  bacterial cell walls that is also incorporated into virus glycoproteins. This 81 
early innate recognition may play a critical step in priming adaptive immune responses to 82 
infection [19]. 83 
 84 
The contribution of ficolins to controlling virus infections is poorly understood. Porcine 85 
ficolin-α reduces infectivity of porcine reproductive and respiratory syndrome virus 86 
(PRRSV) [20]. Human L-ficolin also inhibits infectivity of Influenza A in vivo [21]. A role 87 
for L-ficolin in immune recognition of HCV virions may exist, as binding of a monomeric 88 
recombinant L-ficolin to the HCV envelope glycoproteins has been demonstrated to 89 
activate the complement cascade resulting in cell lysis [22]. However, no direct antiviral 90 
effect on HCV has been described for L-ficolin. Here, the ability of a purified recombinant 91 
oligomeric L-ficolin to directly neutralize HCV was investigated. Interaction of L-ficolin 92 
with recombinant HCV envelope glycoproteins in the context of HCV pseudoparticles 93 
(HCVpp) and cell cultured HCV particles (HCVcc) was found to result in direct inhibition 94 
of virus entry. 95 
 96 
Materials and Methods 97 
Purification of plasma L-ficolin. L-ficolin was isolated from citrated human plasma, using 98 
GlcNac-Sepharose-4B beads according to the method of Cseh et al. [23]. 99 
Expression of recombinant FLAG-tagged L-Ficolin: Human L-ficolin cDNA was amplified 100 
from an IMAGE clone BCO 69572 (Open Biosystem) to create a recombinant amino-101 
terminal FLAG-tagged L-ficolin (primers available upon request). The modified L- ficolin 102 
was cloned into pcDNA-DEST26
 
(Invitrogen) and expressed in HEK 293T cells cultured in 103 
DMEM. Culture supernatants were clarified and L-ficolin purified using anti-FLAG M2 104 
affinity resin (Sigma). L-ficolin was eluted with 175 μgmL-1 FLAG peptide. Fractions were 105 
collected and dialyzed with TBS (50 mM Tris-HCl, pH 8.0, 0.15 M NaCl). Protein 106 
separation was performed on a 10% SDS-PAGE gel, followed by staining with SimplyBlue 107 
(Life Technologies). Western blotting was performed on separated proteins with anti-L-108 
ficolin mAb GN5 (Hycult) or anti-FLAG mAb (Sigma). Total protein concentration was 109 
determined using a Bicinchoninic Acid (BCA) assay (Pierce), while active L-ficolin was 110 
measured using an acetylated-BSA binding assay (supplementary methods). 111 
L-ficolin HCV glycoprotein binding assay and inhibition. HCV glycoproteins E1/E2 and 112 
6xhis-tagged soluble E2 constructs were described previously [24,25]. Maxisorp plates 113 
were coated with anti-L-ficolin antibody GN5 (Hycult) in PBS and incubated at 4
o
C 114 
overnight. Plates were blocked with PBS-Tween, 5% milk and incubated with 5μg/mL L-115 
ficolin. Lysates containing HCV glycoproteins E1/E2 derived from genotype 1 (H77c; 116 
Accession number AF011751), diluted 1⁄10 in PBS–Tween, or purified sE2 (4 μg/mL) in 117 
PBS-Tween were added. A cell lysate from untransfected 293T cells was included as a 118 
negative control. After washing, 1µgmL
-1
 biotinylated mAb AP33 [26] was added for 1 119 
hour. After washing three times, wells were incubated for 30 minutes with 0.5 µgmL
-1
 120 
HRP-conjugated streptavidin. Binding was detected at 620nm after incubation with 121 
Tetramethylbenzidine (Sigma). Inhibition experiments were performed with an additional 122 
step after L-ficolin incubation, adding 100µL/well of serial dilutions of either GlcNAc, 123 
CysNAc, or D-Mannose. After 1 hour, the plates were washed three times before addition 124 
of HCV glycoproteins. 125 
 126 
Neutralization of pseudovirus entry. HCV pseudoparticles (HCVpp) were prepared as 127 
previously described [27] incorporating E1/E2 glycoproteins from HCV genotype 1a 128 
(H77c; AF011751), 2a (JFH1; AB047639), 3a (UKN3A13.6; AY894683) and genotype 4a 129 
(UKN4.11.1; AY734986). Pseudoparticles possessing the VSV G protein were also 130 
produced. Infectivity of purified pseudoparticles was assessed using Huh7 cells, incubating 131 
particles with purified L-ficolin preparations (quantified by either BCA assay or functional 132 
binding assay) for one hour in Dulbecco’s Modified Eagle Media (DMEM) before addition 133 
to target cells. A fraction from the L-ficolin purification process containing no detectable 134 
protein (determined by BCA assay) was used as a control. Luciferase activity was assessed 135 
after 72 hours. Neutralization assays with HIV-1 pseudoviruses were performed essentially 136 
in the same manner, using glycoproteins from strain HXB2. Infection of TZM-bl cells was 137 
performed as previously described [28]. To assess any effect of L-ficolin on Huh7 cells, 138 
fractions containing L-ficolin oligomers (or controls) were incubated with cells at 4ºC for 139 
one hour prior to washing with PBS and addition of pseudoviruses.  140 
Neutralization of cell cultured HCV (HCVcc) infection. Neutralization assays with JFH1 141 
HCVcc were performed as previously described [27], using similar conditions to those of 142 
HCVpp assays. Neutralization was performed with 100FFU of virus, and different 143 
concentrations of purified L-ficolin protein. The effect of calcium was determined using an 144 
approximate IC50 concentration of oligomeric L-ficolin in the presence of 2mM or 7mM 145 
CaCl2. Infection was determined by staining for the presence of HCV NS5A using antibody 146 
9E10 [29]. Neutralization was calculated by as a percentage of an uninhibited control. 147 
Statistical analysis. Unpaired t tests or one-way ANOVA tests were used as appropriate to 148 
determine differences between mean binding/neutralization values. Serum concentrations 149 
of L-ficolin in different groups of individuals were compared using a Mann-Whitney U test. 150 
 151 
Results 152 
In vitro expressed recombinant L-ficolin forms oligomers similar to serum-purified L-153 
ficolin. Natural L-ficolin exists as oligomers of a 35kD subunit, up to and including a 154 
dodecamer form (Figure 1A). These oligomers were observed for fractions of L-ficolin 155 
purified from human serum after passage through a GlcNAc-Sepharose matrix and elution 156 
with soluble GlcNAc (Figure 1B, left panel). Proteins observed at 35 kDa, 70 kDa, and 157 
above 250 kDa represented monomers, dimers, and higher order oligomers, respectively. 158 
Consistent with previous reports [30], proteins were also observed at molecular masses 159 
greater than the expected dodecamer, suggesting that L-ficolin is able to form covalently-160 
linked higher molecular weight oligomers. Under reducing conditions the oligomers of 161 
serum L-ficolin were reduced to a molecular mass of 35 kDa (Figure 1B, right panel), with 162 
traces of dimer or trimer. Recombinant FLAG-tagged, affinity purified L-ficolin was 163 
observed as a similar mixture of monomers and oligomers, both when probed with anti-L-164 
ficolin mAb (Figure 1C), and with anti-FLAG mAb (Figure 1D), indicating that the 165 
recombinant protein possesses similar structure to the in vivo form. Under these non-166 
reducing conditions, higher oligomers including a possible dodecamer complex were 167 
observed. Treatment with dithiothreitol resulted in only the monomeric recombinant protein 168 
resolved by western blot (Figure 1E). 169 
 170 
Recombinant L-ficolin interacts with HCV glycoproteins. Two recombinant 171 
glycoprotein constructs derived from the HCV infectious clone H77c [31] were used to 172 
model the interaction between L-ficolin and HCV virions. Binding of both recombinant L-173 
ficolin and L-ficolin purified from serum to the E2 glycoprotein ectodomain (aa363-661) 174 
was comparable (Figure 2A). This was confirmed by dose-dependent binding of 175 
recombinant L-ficolin to E1/E2 heterodimers (aa170-746) (Figure 2B).  176 
 177 
Pre-incubating L-ficolin with ligands resulted in competition for E2 binding (Figure 2C). 178 
Both N-acetyl-cysteine (CysNAc) and GlcNAc inhibited the binding interaction between 179 
recombinant L-ficolin and the E2 ectodomain in a dose-dependent manner. Fifty per cent 180 
inhibition was achieved with 1.8 mM CysNAc, and 260 mM GlcNAc. At the greatest 181 
concentration tested (1 M), the MBL ligand D-Mannose had no effect on binding.  182 
 183 
 L-ficolin neutralizes genetically diverse HCV strains. Having demonstrated an 184 
interaction between recombinant L-ficolin and the HCV glycoproteins, the effect of L-185 
ficolin on entry of HCVpp possessing the HCV glycoproteins isolated from patient viruses 186 
was investigated. Before performing these experiments the expression of L-ficolin by target 187 
Huh7 cells was assessed. No cellular expression of L-ficolin in the target cells was 188 
observed, either by immunofluorescence or by quantitative RT-PCR of L-ficolin mRNA 189 
(data not shown). Glycoproteins derived from genetically diverse HCV viruses were tested 190 
in a pseudoparticle entry assay (Figure 3A). Active L-ficolin in the preparation was 191 
quantified using a functional assay binding to acetylated-BSA. At a concentration of 192 
1μgmL-1 active protein almost complete inhibition of entry of pseudoparticles reconstituted 193 
with strains H77 (genotype 1a), UKN3A13.6 (genotype 3a) and UKN4.11.1 (genotype 4) 194 
was observed (Figure 3A). A control fraction from the purification procedure containing no 195 
L-ficolin (as determined by western blot and BCA assay) had no inhibitory effect when 196 
diluted equivalently. Entry of pseudoparticles bearing VSV G was also neutralized by L-197 
ficolin, but this L-ficolin preparation had no effect on entry of retroviral pseudoparticles 198 
bearing HIV glycoproteins into CD4+/CCR5+ TZM-bl cells, eliminating the possibility of 199 
non-specific toxicity (Figure 3A).  Recombinant L-ficolin was further separated into three 200 
fractions containing a mixture of oligomers/monomers, or only monomers, as analyzed by 201 
western blot (Figure 3B) and stained SDS-PAGE (Figure 3C). Consistent with the greater 202 
sensitivity of western blotting, protein was only observed in sample F1 in the stained gel. 203 
No contaminating protein was observed. Total protein was quantified in these samples by 204 
BCA assay. Samples F1, F2 and F3 possessed 157µgmL
-1
, 46µgmL
-1
, and 10µgmL
-1
 205 
protein, respectively. Each sample was diluted to 1µgmL
-1
 total protein and assessed for 206 
neutralizing potency against HCVpp possessing the glycoproteins from strain JFH1 (Figure 207 
3D). Fraction 1 neutralized HCVpp entry by >60%. Fractions 2 and 3 demonstrated no 208 
significant inhibition. A negative control fraction possessed no neutralizing activity. To 209 
exclude the possibility that the small neutralizing effect of fractions 2 and 3 might be due to 210 
the presence of residual FLAG peptide in the eluted material, neutralization experiments 211 
with this peptide demonstrated no effect on the entry of HCV pseudoparticles (not shown). 212 
Given that the negative fraction was treated identically and had no effect on entry it is most 213 
likely that the neutralizing effect was due to small quantities of oligomeric L-ficolin in 214 
these fractions. The sample possessing detectable oligomeric L-ficolin consistently had 215 
significantly greater neutralizing effect than any other sample tested. This sample was 216 
further found to inhibit the entry of cell-cultured HCV (HCVcc) of strain JFH-1. Sample 217 
F1, at a stock of 157µgmL
-1
 was serially diluted in parallel with the negative fraction before 218 
incubation with HCVcc. Neutralization by F1 was dose-dependent, with an EC50 of 219 
1.2µgmL
-1 
(Figure 3F), while no inhibition was observed for the negative fraction. 220 
 221 
To eliminate the possibility that the observed neutralizing effect was a result of L-ficolin 222 
interacting with the target cells, pre-incubation experiments were performed with a 223 
preparation of L-ficolin. Neutralization was only observed when pseudoparticles were pre-224 
incubated with the L-ficolin-containing sample (Figure 4). 225 
 226 
L-ficolin neutralizes cell cultured HCV in a calcium-dependent manner. L-ficolin 227 
binding has been described to be partially calcium-dependent [32]. To determine if this is 228 
the case for recognition of HCV, neutralization experiments were performed using the 229 
HCVcc in the presence of different concentrations of CaCl2. HCVcc particles were 230 
prepared in media containing a basal level of 2mM CaCl2, or media supplemented to a final 231 
concentration of 7mM CaCl2. Using 1.6µgmL
-1
  L-ficolin in this assay, enhanced 232 
neutralization was observed with increasing calcium chloride concentration, indicating that 233 
this activity is, at least in part, calcium-dependent. This is likely to be caused by 234 
interactions between the S1 binding site and the GlcNAc present on the surface of HCV 235 
particles. When L-ficolin treated with 7mM CaCl2 was analyzed by western blot, no 236 
difference in patterns of oligomerization was observed (Figure 5B). Consistent with 237 
previous reports [30], the action of calcium is likely to be on binding activity, rather than 238 
disulphide-mediated oligomerization. 239 
 240 
Inibition of HCV entry by L-ficolin ligands. To further assess the binding specificity to 241 
the observed neutralization, inhibition experiments with GlcNAc and CysNAc were 242 
performed. At the concentrations demonstrated to inhibit interaction of E2 with L-ficolin, 243 
both GlcNAc (data not shown) and CysNAc (Supplementary Figure 1) were also found to 244 
inhibit entry in the absence of L-ficolin. As such, any blocking effect of L-ficolin 245 
neutralization was not resolvable.  This unexpected result could be evidence that cellular 246 
receptors involved in HCV entry recognize similar acetyl-containing molecular entities as 247 
the ficolin, so that acetyl-containing inhibitors (GlcNAc and CysNAc) also competitively 248 
inhibit these interactions. To investigate this further, CysNAc was incubated with either 249 
HCV, VSV or HIV-1 pseudoviruses, or target cells, prior to infection (Supplementary 250 
Figure 1B). Treatment of both HCVpp and VSVpp with CysNAc resulted in reduction in 251 
infectivity, but no effect on HIV-1 entry was observed. It is possible that VSV and HCV 252 
share interactions with receptors that interact with this ligand. Unexpectedly, treatment of 253 
target cells with CysNAc resulted in a significant increase in entry of HIV-1pp, but not 254 
HCVpp or VSVpp. This finding is worthy of further investigation, and may be linked to the 255 
plasma-membrane fusion event of HIV-1 compared to the endosomal fusion of VSV and 256 
HCV. The lack of inhibition of pseudovirus entry with CysNAc pre-treated cells suggests 257 
that this blocking effect is mediated on the virus, rather than the cells, and is not attributed 258 
to cell cytotoxicity. Visual inspection of Huh7 cells treated with CysNAc (Supplementary 259 
figure 1C) confirmed that no cell death occurred in treated cells, but revealed a visible 260 
change in cell morphology and size, which may be linked to altered receptor expression and 261 
resistance to HCV entry. 262 
 263 
L-ficolin neutralizes HCV entry at physiologically relevant levels. As many proteins can 264 
inhibit viruses at high concentrations, we next determined if the concentration of L-ficolin 265 
that resulted in in vitro neutralization was physiologically relevant in both healthy donors 266 
and a HCV-infected cohort of patients. Serum L-ficolin was quantified by ELISA in the 267 
sera taken from healthy donors and patients with chronic HCV infection (Supplementary 268 
Figure 2). There was no significant difference between the median L-ficolin concentrations 269 
in healthy donors (4.6μg mL-1 S.D. ±1.5) or chronic HCV infections (4.2μg mL-1 S.D. 270 
±1.9) (Mann-Whitney U test, p=0.29). This confirmed that the concentration of L-ficolin 271 
that neutralizes HCV entry in vitro is biologically relevant, and that individuals with 272 
chronic HCV infection do not have impaired capacity to produce L-ficolin. 273 
 274 
 275 
Discussion 276 
The soluble innate immune effector L-ficolin has been implicated in the control of a range 277 
of infectious diseases, acting as an opsonin and activating complement upon binding to 278 
glycosylated targets [33]. Here we demonstrated that a recombinant, oligomeric L-ficolin 279 
mediates direct neutralization of HCV entry.  280 
 281 
A key advance was the expression of correctly-folded oligomeric recombinant L-ficolin in 282 
human cells, in contrast to previous studies using bacterially-expressed protein that yielded 283 
only monomers [22]. The monomeric form of L-ficolin was described to activate the 284 
complement cascade and facilitate complement-mediated lysis of HCV infected cells, but 285 
not to inhibit HCV entry. The N-terminal FLAG-tag used for purification had no significant 286 
effect on the oligomerization of the recombinant L-ficolin polypeptides, and this oligomer 287 
possessed binding equivalent to serum-purified protein. This construct provides a useful 288 
tool for further investigations of the direct anti-viral properties of L-ficolin. 289 
 290 
Acetylated sugars are defined ligands for L-ficolin [14]. It is likely that the high mannose 291 
oligosaccharides present on the surface of E1/E2 possessing a GlcNAc2 stem are binding 292 
targets for L-ficolin [34,35]. There is evidence that two of the N-linked glycosylation sites 293 
might possess complex glycans containing terminal GlcNAc residues at residues 423 and 294 
430 [7]. These asparagines have been implicated in the entry of HCVpp [8], and HCVcc 295 
[9], respectively. The neutralization of entry of HCVcc and HCV pseudoparticles 296 
representing HCV genotypes 1, 2, 3 and 4 is consistent with a role for conserved E1/E2 297 
glycans in HCV entry. The genotype 3a clone used in this study has previously been 298 
described to be resistant to neutralization by broadly-neutralizing antibodies [27,36].  L-299 
ficolin effectively neutralized this isolate, indicating possible therapeutic application for 300 
inhibiting entry of antibody neutralization-resistant HCV strains. Consistent with previous 301 
reports demonstrating interaction of L-ficolin with GlcNAc [17] and CysNAc [32], both 302 
ligands inhibited interaction of recombinant L-ficolin with glycoprotein E2, suggesting 303 
interaction of the fibrinogen-like domain and N-linked glycans. Four discrete binding sites 304 
in the L-ficolin fibrinogen-like domain have been identified (S1-4), which possess different 305 
binding specificities [37]. This may account for the difference observed in competition 306 
assays with the ligands GlcNAc and CysNAc; although they both bind in the S2 site, 307 
GlcNAc also binds around the S1 site, while CysNAc is able to bind to site S3, and at high 308 
concentrations, to other sites with little structural interaction [37]. The unexpected 309 
discovery that both GlcNAc and CysNac inhibited HCV entry in vitro also raises new 310 
questions about the nature of virus-cell interactions. It is possible that these ligands alter 311 
expression of host receptors, and is worthy of further investigation.  312 
The calcium-dependent nature of the neutralizing activity suggested that the accessibility of 313 
the binding site on L-ficolin is modulated by the presence of a Ca
2+
 ion as previously 314 
described [16]. As the fibrinogen-like domain possesses multiple binding sites with 315 
differential specificities, the exact interactions between the HCV glycoproteins with the 316 
binding surface of L-ficolin remain to be determined.  We also eliminated the possibility 317 
that L-ficolin interactions with target cells make them refractory to virus entry, 318 
demonstrating a virion-specific effect. The exact molecular interaction between L-ficolin 319 
and E1/E2 is currently under investigation. 320 
 321 
Recombinant oligomeric L-ficolin inhibited entry of both HCV and VSV pseudoviruses. It 322 
is still not understood what common factor determines this sensitivity to L-ficolin 323 
neutralization, but this molecule has potential for application as an entry inhibitor for other 324 
enveloped viruses. It is plausible that neutralization specificity is associated with specific 325 
modifications to carbohydrates on the glycoprotein surface. This neutralizing activity is 326 
consistent with the ability of porcine ficolin-α to bind and neutralize PRRSV. Ficolin-α 327 
reduced cytopathic effect of PRRSV and inhibited replication of infectious viral particles 328 
[20]. However, soluble lectins have also been demonstrated to inhibit antibody 329 
neutralization of Human Immunodeficiency Virus 1 [38], suggesting that complex 330 
interactions might take place at the surface of the virion.  331 
 332 
It remains to be demonstrated if binding of this oligomeric L-ficolin construct to HCV 333 
might result in secondary anti-viral properties that are therapeutically useful. L-ficolin 334 
might contribute to viral clearance through activation of serine proteases activating the 335 
complement cascade. Complement is an essential component of the anti-viral immunity to 336 
other flaviviruses [39], and is likely to contribute to protection against HCV infection [22]. 337 
Indirect evidence supports an anti-viral role for the complement cascade, as both HCV 338 
NS5A and Core proteins inhibit complement component C4 transcription. Protectin (CD59) 339 
is also incorporated into HCV virions [40] suggesting that HCV has evolved multiple 340 
strategies to evade complement-dependent lysis. It is possible that L-ficolin mediated 341 
complement activation might contribute to in vivo elimination of HCV particles as well as 342 
infected cells.  343 
 344 
We assayed the concentration of L-ficolin expressed in the serum of healthy individuals 345 
and people chronically infected with HCV, finding that the range is consistent with that 346 
previously reported in healthy cohorts [41]. While we appreciate that the localized 347 
concentration of L-ficolin might be higher at the site of synthesis in the liver, this provides 348 
evidence that neutralizing concentrations of L-ficolin are circulating in human sera. The 349 
proportion of HCV virions that circulate as complexes with L-ficolin remains to be 350 
determined. It was also noted that any liver damage caused by chronic HCV infection did 351 
not result in reduced L-ficolin expression in these individuals. 352 
This study highlights the potential for an oligomeric recombinant L-ficolin as a novel 353 
therapeutic entry inhibitor for HCV infection. The broad, potent antiviral activity might 354 
also be applied to inhibition of entry of by other enveloped viruses possessing acetylated 355 
glycoproteins. It also has identified a previously unreported antiviral activity of the L-356 
ficolin ligand N-acetylcysteine. 357 
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 485 
486 
Figure Legends 487 
Figure 1. Expression of recombinant, oligomeric human L-ficolin. A) Schematic 488 
illustrating the structure of L-ficolin. Each polypeptide monomer possesses a cysteine-rich 489 
N-terminal domain, a collagen-like domain, a neck region, and a C-terminal fibrinogen-like 490 
domain. Monomers oligomerize into dodecamers formed of trimeric subunits. B) L-ficolin 491 
was purified from human serum using GlcNAc-Sepharose. The flow-through (F), mannose 492 
wash (M), and L-ficolin eluate fractions (lanes 1-7) were detected by western blot with 493 
mAb GN5 following non-reducing (NR) or reducing (R) SDS-PAGE. Serum L-ficolin 494 
oligomers appeared as a 35kDa monomer, 70kD dimers and ~250kD oligomers, as well as 495 
higher-order multimers. C & D) Expression of recombinant L-ficolin. In vitro expressed L-496 
ficolin was purified using an anti-FLAG M2 affinity resin. L-ficolin samples were resolved 497 
using non-reducing PAGE and western blotting with anti L-ficolin antibody, GN5 (C) or 498 
anti-FLAG mAb M2 (D). Each blot presents reactivity with start material (S), flow through 499 
(F) and eluted L-ficolin (E). Monomeric (35kDa), dimeric (~70kDa), and multimeric forms 500 
(250kD) of recombinant L-ficolin were observed. E) Eluted material was analyzed under 501 
non-reducing conditions (NR) or reduced in the presence of dithiothreitol (R), 502 
demonstrating the reduction of oligomers (o) to monomers (m). 503 
 504 
 505 
 506 
Figure 2. Recombinant L-ficolin binds to HCV glycoproteins E1 and E2 in an acetyl-507 
specific manner. A) L-ficolin binding to recombinant HCV glycoproteins was evaluated 508 
by ELISA. E2 was captured using mAb GN5-immobilised L-ficolin and detected by anti-509 
E2 antibody. Equivalent, dose-dependent interaction was observed between the soluble 510 
ectodomain of HCV E2 (sE2661) and both recombinant L-ficolin () or purified serum L-511 
ficolin (). The highest concentration of sE2661 was incubated with mAb GN5 in the 512 
absence of L-ficolin as a control (). B) Dose-dependent binding of L-ficolin to 293T cell 513 
lysates from cells transfected with E1/E2 (), or mock-transfected cells (). C) 514 
Immobilized L-ficolin was pre-incubated with the indicated concentrations of L-ficolin 515 
ligands GlcNAc (▼),CysNAc (), or D-Mannose (), prior to binding sE2. Binding is 516 
presented as a proportion of binding in the absence of inhibitor. IC50 values were 260mM 517 
(GlcNAc), and 1.8mM (CysNAc). No inhibition by D-Mannose was observed.  518 
 519 
Figure 3. L-ficolin-mediated neutralization of HCV entry A) Retroviral pseudoparticles 520 
possessing envelope glycoproteins E1/E2 from strains of HCV representing genotypes 1a 521 
(H77c), 3a (UKN3A13.6), or 4a (UKN4.11.1), the VSV G protein, or HIV-1 gp160 were 522 
treated for one hour at room temperature with purified recombinant L-ficolin (grey bars) or 523 
a control fraction from purification containing no L-ficolin (black bars), before infecting 524 
Huh7 cells. All of the HCVpp and the VSV G pseudoparticles were neutralized by L-525 
ficolin. No inhibition of entry of pseudoparticles bearing HIV-1 glycoproteins into TZM-bl 526 
cells was observed. Data is presented as the proportion of infectivity in the absence of 527 
inhibitor. B) FLAG-tagged L-ficolin expressed into the supernatants of HEK293T cells was 528 
fractionated by affinity purification on FLAG resin and pooled into three independent 529 
fractions (fractions F1, F2 and F3), as well as a negative fraction containing no L-ficolin 530 
(N) These fractions contained 157 µgmL
-1
, 46 µgmL
-1
, 10 µgmL
-1
 and 0 µgmL
-1 
total 531 
protein, respectively. C) When analyzed by staining an SDS-PAGE gel, protein was only 532 
detected in sample F1. D) The fractions were each diluted to 1 µgmL
-1
 total protein and 533 
assessed for neutralization of entry of HCVpp bearing JFH1 E1/E2 glycoproteins. Data is 534 
presented as a proportion of an uninhibited control. Significant neutralization was only 535 
exhibited for the fraction containing detectable oligomeric L-ficolin (** p<0.01).  E) The 536 
F1 fraction was found to neutralize entry of the JFH1 strain of cell-cultured HCV in a dose 537 
dependent manner (IC50= 1.2µgmL
-1
), while no inhibition was observed with the negative 538 
control sample. 539 
 540 
Figure 4. Neutralization of HCV entry by L-ficolin requires interaction with virus 541 
particles. Protein fractions containing oligomeric L-ficolin, or a control with no detectable 542 
L-ficolin diluted equivalently, were incubated with either HCVpp (strain H77), or target 543 
Huh7 cells. Following washing, cells were infected with HCVpp. >50% neutralization was 544 
only observed when L-ficolin was pre-incubated with virus particles.  A significant 545 
difference was observed between virus and cells treated with L-ficolin, compared to cells 546 
treated alone (1-way ANOVA; * p<0.05). No significant differences in entry were observed 547 
when cells were treated with L-ficolin or a negative control. 548 
 549 
Figure 5. Inhibition of HCV entry is calcium-dependent. A) Infection assays were 550 
prepared with cell-culture grown HCV. Neutralization was performed with approximately 551 
50% neutralizing concentrations of oligomeric L-ficolin in the presence of 2mM CaCl2 552 
(black bars) or 7mM CaCl2 (grey bars). Neutralization was compared to a positive 553 
uninhibited control, and a sample treated with an equivalent L-ficolin-negative fraction 554 
from purification. Greater neutralization of HCVcc was observed with L-ficolin fractions in 555 
the presence of 7mM CaCl2. (One-way ANOVA; ** p<0.01, *** p<0.001). B) Ficolin was 556 
incubated in PBS +/-7mM CaCl2 before analysis by SDS-PAGE/western blotting with mAb 557 
GN5. No difference in oligomerization was observed in the presence of CaCl2. 558 
 559 
 560 
561 
 562 
563 
564 
565 
566 
 567 
